Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GLYC's SEC filings document material-event disclosures for the registrant, including operating and financial results, material agreements, shareholder voting matters, capital-structure updates, governance matters, and security-structure disclosures. Recent Form 8-K reporting also covers executive compensatory arrangements, including an executive severance plan, and identifies the registrant in the filing record as Crescent Biopharma, Inc.
The filing record provides formal disclosure on corporate actions, financial reporting items, governance approvals, and other matters affecting the public-company structure associated with the GLYC issuer record.
Form 3 highlights for GlycoMimetics Inc. (now Crescent Biopharma, Inc.)
On 06/23/2025 Fairmount Funds Management LLC and its affiliated investment vehicle Fairmount Healthcare Fund II L.P. filed an Initial Statement of Beneficial Ownership (Form 3) following the closing of a complex restructuring that included (i) a two-step merger between GlycoMimetics, Inc. and privately held Crescent Biopharma, Inc. completed on 06/13/2025 and (ii) a redomicile from Delaware to the Cayman Islands effective 06/16/2025.
Equity position disclosed
- Ordinary shares: 1,387,866 shares held indirectly by Fairmount Healthcare Fund II L.P.
- Series A Non-Voting Convertible Preferred Shares: 2,890 shares, convertible into 2,890,000 ordinary shares; no expiration date and subject to a beneficial-ownership cap.
- Pre-funded warrants: 1,636,706 warrants exercisable at $0.001 per share; no expiration date but capped at 9.99% ownership upon exercise.
Aggregating the ordinary shares, the preferred share conversion amount, and underlying warrant shares, Fairmount controls or can acquire up to approximately 5.9 million ordinary shares. This exceeds the 10 % ownership threshold, and the filing confirms the filer’s dual status as both a director by deputization (through Peter Harwin) and a 10 % beneficial owner.
Key structural details
- Each Crescent common share exchanged for 0.1445 ordinary shares of the issuer.
- Each share of Crescent Seed Preferred exchanged for 0.0001445 Series A Preferred Shares.
- All Crescent pre-funded warrants exchanged 1:1 (0.1445 ratio applied) into issuer pre-funded warrants.
No cash consideration, valuation data, or earnings metrics are provided in the Form 3. The filing mainly establishes the post-merger and post-redomicile capital structure and confirms Fairmount’s governance role and sizable equity stake.
Form 3 Overview: David Charles Lubner filed an initial statement of beneficial ownership following the closing of GlycoMimetics Inc.’s reverse-merger with Crescent Biopharma on 13 June 2025 and the company’s subsequent redomiciliation to the Cayman Islands on 16 June 2025. At the effective time, GlycoMimetics adopted the new corporate name “Crescent Biopharma, Inc.”.
Reporting person & role: Lubner is disclosed as a director; no other insider roles were indicated.
Securities reported:
- 20,164 stock options to purchase ordinary shares at an exercise price of $9.56 per share.
- 1,120 options already vested; the remaining 19,044 vest monthly through 14 April 2028, contingent on continued service.
Corporate actions referenced:
- Two-step merger whereby Crescent became a wholly owned subsidiary and GlycoMimetics simultaneously renamed itself Crescent Biopharma, Inc.
- Conversion of the Delaware corporation into a Cayman Islands exempted company; all existing options automatically converted into equivalent Cayman ordinary-share options.
This filing is administrative in nature, providing baseline ownership for a newly appointed director after the merger and redomiciliation. No open-market purchases, sales, or new compensatory grants were disclosed beyond the option rollover.
Form 3 overview: Director Susan Moran filed an initial beneficial ownership report following GlycoMimetics, Inc.’s transformative merger with Crescent Biopharma and immediate re-branding to Crescent Biopharma, Inc. ("Issuer"). The filing date of record is 13 Jun 2025.
Equity position disclosed: Moran holds a single derivative security—an option to purchase 20,164 ordinary shares at an exercise price of $6.16, expiring 11 Dec 2034. Of these, 3,360 options are fully vested; the remaining 16,804 vest in equal monthly tranches through 11 Dec 2027, contingent on continued board service.
Corporate actions driving the filing:
- Two-step merger (First Merger & Second Merger) completed 13 Jun 2025: GlycoMimetics created and merged two wholly-owned subsidiaries with Crescent Biopharma, leaving Crescent as a wholly-owned operating subsidiary.
- Post-merger, GlycoMimetics adopted the Crescent Biopharma name.
- Re-domicile: On 16 Jun 2025 the Issuer converted from a Delaware corporation to a Cayman Islands exempted company. All outstanding U.S. equity awards were automatically converted into rights over Cayman ordinary shares on identical terms.
Implications for investors: The Form 3 itself does not alter outstanding share count or economics, but it formalises insider ownership under the new capital structure, confirms option continuity across the merger and re-domicile, and signals that governance reporting has transitioned to the Cayman entity.
Schedule 13D/A Amendment No. 1 filed on 20 June 2025 discloses that Adage Capital Management, L.P., its co-founders Robert Atchinson and Phillip Gross (together, the “Reporting Persons”) now beneficially own 50,912 ordinary shares of Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.) after the issuer’s 1-for-100 reverse stock split and completion of a merger/redomestication on 13-16 June 2025.
The stake represents 0.37 % of the 13,892,562 shares outstanding, pushing the Reporting Persons below the 5 % threshold that triggers Schedule 13D reporting. No share transactions occurred in the past 60 days; the percentage change is entirely attributable to the share-count increase that accompanied the merger. As a result, this filing is designated the final amendment; Adage and its principals are voluntarily exiting the beneficial-ownership reporting system for the issuer.
Voting and dispositive power remain shared among the Reporting Persons, with no sole power disclosed. Adage Capital Partners retains rights to dividends and sale proceeds. The amendment contains no indication of future investment intentions or disposition plans.